Back to results
US 12,083,170 B2Granted
Prohemostatic proteins for the treatment of bleeding
AssigneeAcademisch Ziekenhuis Leiden
InventorsDaniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
Life of this patent
Estimating the term…
Abstract
Described are recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
Claims11
A recombinant protein comprising:
- a coagulation factor Xa polypeptide having an alteration in a region of amino acid residues corresponding to the region of amino acid residues between His-311 and Asp-320 of SEQ ID NO:
- 1,
- wherein the alteration is an insertion of from 1-20 amino acid residues.
A pharmaceutical composition comprising:
- a protein or a pharmaceutically acceptable salt thereof, wherein the protein is SEQ ID NO:
- 1 with an insertion of from 9 to 13 natural amino acid residues between His-311 and Asp-320 of SEQ ID NO:
- 1,
- a pharmaceutically acceptable carrier, and
- one or more of diluents, fillers, salts, buffers, stabilizers, and solubilizers.
2 more elements
Dependencies are inferred from the claim text.